Here's Why Steris (STE) is a Strong Growth Stock

Zacks identifies STERIS (STE), a medical technology firm, as a notable growth stock despite its #3 (Hold) Zacks Rank, due to its 'A' ratings for Growth and overall VGM Style Scores. The company is projected for 12.5% year-over-year earnings growth, supported by recent upward revisions in its FY2026 earnings consensus estimate, which increased by $0.24 to $10.37 per share, suggesting it warrants consideration for growth-oriented portfolios.

Analysis

STERIS plc (STE) presents a nuanced investment case, characterized by a neutral Zacks #3 (Hold) rank that contrasts with strong underlying growth indicators. The company scores an 'A' for its Growth Style Score, supported by a forecast for 12.5% year-over-year earnings growth for the current fiscal year. This forward-looking optimism is substantiated by recent analyst activity for fiscal 2026, where two upward estimate revisions in the past 60 days have pushed the Zacks Consensus Estimate up by $0.24 to $10.37 per share. Furthermore, STE has a track record of consistently meeting or exceeding expectations, evidenced by an average positive earnings surprise of 2%. The overall 'A' rating for its composite VGM (Value, Growth, Momentum) score suggests a well-rounded profile that, despite the neutral rank, points to fundamental strength and positive analyst sentiment.

Key Decisions for Investors

• Growth-oriented investors should consider adding STE to their watchlist, as its 'A' grade for Growth and a projected 12.5% earnings increase signal strong fundamental momentum.
• Investors should view the Zacks #3 (Hold) rank as a signal for caution, and monitor for a potential upgrade to a #1 or #2 rank, which would serve as a stronger confirmation of the bullish growth thesis.
• Pay close attention to the trend in earnings estimate revisions, as the recent upward adjustment for fiscal 2026 is a key bullish indicator that could foreshadow a positive re-rating if the momentum in analyst sentiment continues.